Search Results
Oct 27, 2025, 08:54 ET Brave Healer Productions Releases Clear Trauma Now: A Powerful Solution for Getting Unstuck
particularly valuable is Dr. Swack's original investigations into the precise structure of trauma itself, producing a depth of clarity that remains rare even in advanced trauma work. Pairing this understanding with protocols that are highly effective at clearing trauma imprint from the nervous system
More news about: Brave Healer Productions
Oct 27, 2025, 08:49 ET New Book Exposes the Root Causes Behind the Collapse of U.S. Healthcare
IngramSpark. The book offers a rare and powerful insider's perspective on the systemic decline of the American healthcare system, drawing from Dr. Harper's decades of firsthand experience.
More news about: James E. Harper M.D. F.A.C.P.
Oct 27, 2025, 08:31 ET Rare Earths Americas Appoints Board of Directors and Provides Corporate Update
re-domestication to Texas, Rare Earths Americas Ltd. is now Rare Earths Americas, Inc. About Rare Earths Americas Rare Earths Americas is a critical minerals company advancing a portfolio of high-grade, heavy rare earth assets
More news about: Rare Earths Americas
Oct 27, 2025, 08:30 ET Every Patient Matters: Bespoke Digital Endpoint Strategies for Rare Disease Drug Development, Upcoming Webinar Hosted by Xtalks
challenges to implementing imaging in a rare disease population. The speakers will discuss the special considerations for imaging endpoints in paediatric rare diseases. Attendees will also understand the regulatory requirements for assessing QT prolongation in rare disease studies.
More news about: Xtalks
Oct 27, 2025, 08:30 ET Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
disease-specific molecular binding, it can be deployed across multiple drug classes, including mTOR inhibitors, small-molecule anti-angiogenic agents and rare-disease therapeutics. Oncotelic is positioning this as a scalable architecture rather than a one-off formulation, giving the platform multi-asset potential
More news about: NetworkNewsWire
Oct 27, 2025, 08:30 ET AI's Growth Has a Power Problem -- Natural Hydrogen Could Be the Perfect Solution
AI, and that altogether new experiences we've only dreamed of would become possible, is rapidly becoming reality. Technologies like Generative AI are rare; they come about once-in-a-lifetime, and completely change what's possible for customers and businesses. So, we are investing quite expansively, and,
More news about: NetworkNewsWire
Oct 27, 2025, 08:00 ET Ramaco Resources Announces Strategic Initiative to Establish First National Critical Minerals Stockpile at Brook Mine
critical minerals and rare earth elements ("REEs") in the United States. The SMCT stockpile is intended to address both private and public needs for secure, reliable access to rare earth elements and critical minerals vital for the nation's critical rare earth applications. By
More news about: Ramaco Resources, Inc.
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
chest tightness, or skin rash. Posterior Reversible Encephalopathy Syndrome (PRES)PRES is a rare condition that affects the brain and can cause death. Tell your healthcare provider right away if you get any symptoms of PRES during treatment with
More news about: Johnson & Johnson
Oct 27, 2025, 07:15 ET Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid
More news about: Kazia Therapeutics Limited
Oct 27, 2025, 03:30 ET HOW2WORK and SAKA SAKA Partner for the Global Launch (exclude Mainland China) HOW2WORK Collectible Trading Cards: The Monsters Series 3 by Kasing Lung
enhanced durability and visual appeal. The collection includes over 140 unique artworks with different rarity levels: 42 Normal, 42 Rare, 42 Parallel Rare, and 18 Secret Rare (SR/UR). Selected editions also feature autographed cards signed by Kasing Lung, providing collectors with special pieces of lasting
More news about: SAKA SAKA
Oct 27, 2025, 03:30 ET HOW2WORK and SAKA SAKA Partner for the Global Launch (exclude Mainland China) HOW2WORK Collectible Trading Cards: The Monsters Series 3 by Kasing Lung
enhanced durability and visual appeal. The collection includes over 140 unique artworks with different rarity levels: 42 Normal, 42 Rare, 42 Parallel Rare, and 18 Secret Rare (SR/UR). Selected editions also feature autographed cards signed by Kasing Lung, providing collectors with special pieces of lasting
More news about: SAKA SAKA
Oct 26, 2025, 16:53 ET Ribo obtient de l'EMA la désignation de médicament orphelin pour le pARNi thérapeutique RBD1016 contre l'infection par le virus de l'hépatite Delta (VHD)
cette thérapie prometteuse par le biais du développement clinique, dans le but de fournir un nouveau traitement aux patients atteints de cette maladie rare. Plus important encore, elle représente un espoir pour les patients atteints de VHD qui ne disposent pas d'options thérapeutiques efficaces. »
More news about: Ribo Life Science
Oct 26, 2025, 13:07 ET Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In
More news about: Avidity Biosciences, Inc.
Oct 24, 2025, 21:00 ET Rosen Law Firm Encourages Encompass Health Corporation Investors to Inquire About Securities Class Action Investigation - EHC
health care business. But federal data and inspection reports show that some run by the dominant company, Encompass Health Corporation, [. . .] have had rare but serious incidents of patient harm and perform below average on two key safety measures tracked by Medicare." On this news,
More news about: THE ROSEN LAW FIRM, P. A.
Oct 24, 2025, 18:32 ET Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
positive.4 Nipocalimab is continuing to be investigated across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies and Rheumatic diseases.11,12,13,14,15,16,17,18,19,20 The
More news about: Johnson & Johnson
Oct 24, 2025, 13:44 ET PEOPLE Magazine Article, Written by Kennedy Family Authority, Spotlights Revelations from New JFK Biography in Exclusive Feature
Having interviewed hundreds of sources, from presidents and celebrities to the family's most intimate confidantes, McNeil possesses a rare and nuanced understanding of what the public knows, what remains hidden, and what continues to fascinate us about America's most storied family.
More news about: Bancroft Press
Oct 24, 2025, 13:02 ET Sampled and AutoGen Announce Partnership for Specialized Nucleic Acid Extraction and Multiomic Workflows
biopsies, and plant material. Through this partnership, Sampled will refer to AutoGen samples for unique or challenging projects—such as those involving rare sample types, unusual input volumes, or specialized extraction chemistries. AutoGen will refer clients requiring large-scale extractions, analytical
More news about: Sampled
Oct 24, 2025, 12:57 ET The 41st Annual Imagine Benefit, Built on the Legacy of the Rita Hayworth Gala, Raises $1.3 Million to Support the Alzheimer's Association
In a heartfelt mission moment, Tony Award-winning director Rachel Chavkin (Hadestown) and husband Jake Heinrichs shared his family's journey with a rare gene mutation that causes inherited Alzheimer's. The couple highlighted the power of scientific progress in studies such as
More news about: Alzheimer's Association
Oct 24, 2025, 10:20 ET Hope in Syria: Education Cannot Wait investments support teacher training and continued learning for displaced children in Syria
into her mission. In a region where many children have been robbed of their childhood by crises, quality education offers a rare, precious opportunity to rebuild their lives and communities. And teachers like Rudayfah are playing a critical role in this work. Through their commitment,
More news about: Education Cannot Wait
Oct 24, 2025, 09:56 ET Hope in Syria: Education Cannot Wait investments support teacher training and continued learning for displaced children in Syria
into her mission. In a region where many children have been robbed of their childhood by crises, quality education offers a rare, precious opportunity to rebuild their lives and communities. And teachers like Rudayfah are playing a critical role in this work. Through their commitment,
More news about: Education Cannot Wait
Oct 24, 2025, 08:44 ET Direct Dimensions and CAD BLU Announce 3D Scanning & 3D Printing Demo Day in New York City
Showroom, located in New York City's Midtown (250 39th Street, New York, NY 10018). This exclusive open house offers a rare opportunity for professionals and enthusiasts to experience the full range and power of Artec 3D scanning technology, from rapid, handheld scanning
More news about: Direct Dimensions
Oct 24, 2025, 07:29 ET Sobi showcases new data across rare inflammatory conditions at ACR 2025
2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare disease, will be presenting new data across its immunology portfolio at the annual American College of Rheumatology (ACR) Convergence 2025 meeting in
More news about: Swedish Orphan Biovitrum AB
Oct 24, 2025, 05:55 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
The EMA's ODD is assigned to investigational therapies of life-threatening or chronically debilitating rare diseases that affect no more than five in 10,000 individuals in the European Union. The ODD status provides significant regulatory and commercial incentives,
More news about: Ribo Life Science
Oct 24, 2025, 05:43 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
The EMA's ODD is assigned to investigational therapies of life-threatening or chronically debilitating rare diseases that affect no more than five in 10,000 individuals in the European Union. The ODD status provides significant regulatory and commercial incentives,
More news about: Ribo Life Science
Oct 24, 2025, 04:40 ET Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
who originally had "no drugs available." Particularly valuable is that iza-bren enabled some patients to achieve complete response, which is extremely rare in later-line treatment, meaning the possibility of touching cancer cure. For clinical practice, the 303 Study is the first to
More news about: eChinaHealth